Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-02

AUTHORS

N. Kramkimel, A. Thomas-Schoemann, L. Sakji, JL. Golmard, G. Noe, E. Regnier-Rosencher, N. Chapuis, E. Maubec, M. Vidal, MF. Avril, F. Goldwasser, L. Mortier, N. Dupin, B. Blanchet

ABSTRACT

Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF (V600) -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship are lacking. The aim of this prospective, multicenter study was to explore the PK/PD relationship for vemurafenib in outpatients with advanced BRAF-mutated melanoma. Fifty-nine patients treated with single-agent vemurafenib were prospectively analyzed. Vemurafenib plasma concentration (n = 159) was measured at days 15, 30, 60, and 90 after treatment initiation. Clinical and biological determinants (including plasma vemurafenib concentration) for efficacy and safety were assessed using Cox's model and multivariate stepwise logistic regression. Median progression-free survival (PFS) and overall survival were 5.0 (95 % confidence interval [95 % CI] 2.0-6.0) and 11.0 (95% CI 7.0-16.0) months, respectively. Twenty-nine patients (49 %) experienced any grade ≥3 toxicity and the most frequent grade ≥2 toxicity was skin rash (37 %). Severe toxicities led to definitive discontinuation in seven patients (12 %). Grade ≥2 skin rash was not statistically associated with better objective response at day 60 (p = 0.06) and longer PFS (hazard ratio 0.47; 95 % CI 0.21-1.08; p = 0.075). Grade ≥2 skin rash was statistically increased in patients with ECOG ≥ 1 (odds ratio 4.67; 95 % CI 1.39-15.70; p = 0.012). Vemurafenib concentration below 40.4 mg/L at day 15 was significantly associated with a shorter PFS (1.5 [0.5-5.5] vs. 4.5 [2-undetermined] months, p = 0.029). Finally, vemurafenib concentration was significantly greater in patients developing grade ≥2 rash (61.7 ± 25.0 vs. 36.3 ± 17.9 mg/L, p < 0.0001). These results suggest that early plasma drug monitoring may help identify outpatients at high risk of non-response or grade ≥ 2 skin rash. More... »

PAGES

59-69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-015-0375-8

DOI

http://dx.doi.org/10.1007/s11523-015-0375-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1024629328

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26208946


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins B-raf", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Cochin", 
          "id": "https://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, D\u00e9partement de Dermatologie, H\u00f4pital Cochin, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kramkimel", 
        "givenName": "N.", 
        "id": "sg:person.0714461244.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714461244.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paris Descartes University", 
          "id": "https://www.grid.ac/institutes/grid.10992.33", 
          "name": [
            "Centre d\u2019\u00e9tude et de recours sur les inhibiteurs de l\u2019angiog\u00e9n\u00e8se (CERIA), Paris, France", 
            "Assistance Publique H\u00f4pitaux de Paris, Unit\u00e9 Fonctionnelle de Pharmacocin\u00e9tique et Pharmacochimie, H\u00f4pital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France", 
            "UMR8638 CNRS, UFR de Pharmacie, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas-Schoemann", 
        "givenName": "A.", 
        "id": "sg:person.0674476202.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674476202.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Regional et Universitaire de Lille", 
          "id": "https://www.grid.ac/institutes/grid.410463.4", 
          "name": [
            "CHRU de Lille, Service de Dermatologie, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakji", 
        "givenName": "L.", 
        "id": "sg:person.0731117162.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731117162.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Piti\u00e9-Salp\u00eatri\u00e8re Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, D\u00e9partement de Biostatistiques, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Golmard", 
        "givenName": "JL.", 
        "id": "sg:person.01173417137.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173417137.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Cochin", 
          "id": "https://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, Unit\u00e9 Fonctionnelle de Pharmacocin\u00e9tique et Pharmacochimie, H\u00f4pital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Noe", 
        "givenName": "G.", 
        "id": "sg:person.01006222554.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006222554.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Cochin", 
          "id": "https://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, D\u00e9partement de Dermatologie, H\u00f4pital Cochin, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Regnier-Rosencher", 
        "givenName": "E.", 
        "id": "sg:person.0721531217.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721531217.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Cochin", 
          "id": "https://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, Service d\u2019H\u00e9matologie biologique, H\u00f4pital Cochin, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chapuis", 
        "givenName": "N.", 
        "id": "sg:person.01301313751.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301313751.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, D\u00e9partement de Dermatologie, H\u00f4pital Bichat, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maubec", 
        "givenName": "E.", 
        "id": "sg:person.064653677.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.064653677.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paris Descartes University", 
          "id": "https://www.grid.ac/institutes/grid.10992.33", 
          "name": [
            "Centre d\u2019\u00e9tude et de recours sur les inhibiteurs de l\u2019angiog\u00e9n\u00e8se (CERIA), Paris, France", 
            "Assistance Publique H\u00f4pitaux de Paris, Unit\u00e9 Fonctionnelle de Pharmacocin\u00e9tique et Pharmacochimie, H\u00f4pital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France", 
            "UMR8638 CNRS, UFR de Pharmacie, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vidal", 
        "givenName": "M.", 
        "id": "sg:person.01216754433.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216754433.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Cochin", 
          "id": "https://www.grid.ac/institutes/grid.462098.1", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, D\u00e9partement de Dermatologie, H\u00f4pital Cochin, Paris, France", 
            "Institut Cochin, Institut National de la Sante et de la Recherche M\u00e9dicale (INSERM) U1016, Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 8104, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Avril", 
        "givenName": "MF.", 
        "id": "sg:person.014013125204.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014013125204.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Cochin", 
          "id": "https://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Centre d\u2019\u00e9tude et de recours sur les inhibiteurs de l\u2019angiog\u00e9n\u00e8se (CERIA), Paris, France", 
            "Institut Cochin, Institut National de la Sante et de la Recherche M\u00e9dicale (INSERM) U1016, Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 8104, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, Paris, France", 
            "Assistance Publique H\u00f4pitaux de Paris, Service de Canc\u00e9rologie m\u00e9dicale, H\u00f4pital Cochin, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldwasser", 
        "givenName": "F.", 
        "id": "sg:person.0731567765.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731567765.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universit\u00e9 Lille 2 Droit et Sant\u00e9", 
          "id": "https://www.grid.ac/institutes/grid.16780.38", 
          "name": [
            "CHRU de Lille, Service de Dermatologie, Paris, France", 
            "INSERM U 837, Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Lille II, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mortier", 
        "givenName": "L.", 
        "id": "sg:person.0771215027.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771215027.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Cochin", 
          "id": "https://www.grid.ac/institutes/grid.462098.1", 
          "name": [
            "Assistance Publique H\u00f4pitaux de Paris, D\u00e9partement de Dermatologie, H\u00f4pital Cochin, Paris, France", 
            "Institut Cochin, Institut National de la Sante et de la Recherche M\u00e9dicale (INSERM) U1016, Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 8104, Facult\u00e9 de m\u00e9decine, Universit\u00e9 Paris Descartes, PRES Sorbonne Paris Cit\u00e9, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dupin", 
        "givenName": "N.", 
        "id": "sg:person.0664102115.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664102115.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Cochin", 
          "id": "https://www.grid.ac/institutes/grid.411784.f", 
          "name": [
            "Centre d\u2019\u00e9tude et de recours sur les inhibiteurs de l\u2019angiog\u00e9n\u00e8se (CERIA), Paris, France", 
            "Assistance Publique H\u00f4pitaux de Paris, Unit\u00e9 Fonctionnelle de Pharmacocin\u00e9tique et Pharmacochimie, H\u00f4pital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blanchet", 
        "givenName": "B.", 
        "id": "sg:person.0700337302.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700337302.68"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10637-011-9764-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003074905", 
          "https://doi.org/10.1007/s10637-011-9764-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2014.07.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003607426"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004160739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejme1111636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004286834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2013.01.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005388140"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2014.04.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006806779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m112.377218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009999164"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1002011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012824919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjd.12555", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014339721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-013-0058-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014765401", 
          "https://doi.org/10.1007/s40262-013-0058-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0042875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015676476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-014-0137-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019983223", 
          "https://doi.org/10.1007/s40262-014-0137-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-2610", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022246580"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.28709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024462353"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.12685", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024465753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70051-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027593875"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ftd.0000000000000097", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035271330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ftd.0000000000000097", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035271330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(14)70012-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038277880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.43.5362", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041701145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041864150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.5478", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042676361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10637-014-0178-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046029131", 
          "https://doi.org/10.1007/s10637-014-0178-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jchromb.2013.03.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047456287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamadermatol.2013.5278", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048056832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/jdv.12322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048575620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051449373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-013-0108-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051525212", 
          "https://doi.org/10.1007/s40262-013-0108-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-013-0108-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051525212", 
          "https://doi.org/10.1007/s40262-013-0108-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2013.2553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071532515"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2013.2553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071532515"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-02", 
    "datePublishedReg": "2016-02-01", 
    "description": "Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF (V600) -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship are lacking. The aim of this prospective, multicenter study was to explore the PK/PD relationship for vemurafenib in outpatients with advanced BRAF-mutated melanoma. Fifty-nine patients treated with single-agent vemurafenib were prospectively analyzed. Vemurafenib plasma concentration (n\u2009=\u2009159) was measured at days 15, 30, 60, and 90 after treatment initiation. Clinical and biological determinants (including plasma vemurafenib concentration) for efficacy and safety were assessed using Cox's model and multivariate stepwise logistic regression. Median progression-free survival (PFS) and overall survival were 5.0 (95 % confidence interval [95 % CI] 2.0-6.0) and 11.0 (95% CI 7.0-16.0) months, respectively. Twenty-nine patients (49 %) experienced any grade \u22653 toxicity and the most frequent grade \u22652 toxicity was skin rash (37 %). Severe toxicities led to definitive discontinuation in seven patients (12 %). Grade \u22652 skin rash was not statistically associated with better objective response at day 60 (p\u2009=\u20090.06) and longer PFS (hazard ratio 0.47; 95 % CI 0.21-1.08; p\u2009=\u20090.075). Grade \u22652 skin rash was statistically increased in patients with ECOG \u2009\u2265\u20091 (odds ratio 4.67; 95 % CI 1.39-15.70; p\u2009=\u20090.012). Vemurafenib concentration below 40.4 mg/L at day 15 was significantly associated with a shorter PFS (1.5 [0.5-5.5] vs. 4.5 [2-undetermined] months, p\u2009=\u20090.029). Finally, vemurafenib concentration was significantly greater in patients developing grade \u22652 rash (61.7\u2009\u00b1\u200925.0 vs. 36.3\u2009\u00b1\u200917.9 mg/L, p\u2009<\u20090.0001). These results suggest that early plasma drug monitoring may help identify outpatients at high risk of non-response or grade \u2265\u20092 skin rash.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11523-015-0375-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "name": "Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma", 
    "pagination": "59-69", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7555d0ed37f88fd4244dbbfdaeb5f613b9389ec2e66fd76aedbe095d5b486c42"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26208946"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101270595"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-015-0375-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1024629328"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-015-0375-8", 
      "https://app.dimensions.ai/details/publication/pub.1024629328"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000522.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11523-015-0375-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-015-0375-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-015-0375-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-015-0375-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-015-0375-8'


 

This table displays all metadata directly associated to this object as RDF triples.

343 TRIPLES      21 PREDICATES      74 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-015-0375-8 schema:about N06ece91d16244729adf5741efc67b15b
2 N16a3719b409543738f6e3f7f095b5ef8
3 N224706ae42454e64a0bb9c0e03355894
4 N2458e8c5c8f24e9b9370dafb827f1b75
5 N26022bc4fc6a4e20b6fef6a0d990044f
6 N2aaabcd892404f1ebd7fc2d1b574a1b9
7 N3c751e3cc55e4da1ad13a48910b1938a
8 N5ea7d35794624c97b066c4c056bde389
9 N8a113be9f10a4ee99b0bbbe9248a9233
10 N8fb4a04137664aa393b9ae9eb9c6015d
11 Na120ca395d524ed59ba1af879ec3c01b
12 Na42995b51eaa447fabc1a5e7114f1f2c
13 Nac77903b9f714419a4bb3181ebdebe6e
14 Ne18d94025afd4f13b2c7ea85f135c1a5
15 Nf97a1c7836a943d18f5144ca048e9838
16 Nfd94762e7164428e80746248e43f87d5
17 Nff8f115b8e2b452db3519d4bca56a8e6
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N4c1276b9674c433e97f5f945e943b1ae
21 schema:citation sg:pub.10.1007/s10637-011-9764-8
22 sg:pub.10.1007/s10637-014-0178-2
23 sg:pub.10.1007/s40262-013-0058-5
24 sg:pub.10.1007/s40262-013-0108-z
25 sg:pub.10.1007/s40262-014-0137-2
26 https://doi.org/10.1001/jamadermatol.2013.5278
27 https://doi.org/10.1002/cncr.28709
28 https://doi.org/10.1016/j.critrevonc.2014.07.005
29 https://doi.org/10.1016/j.ejca.2013.01.015
30 https://doi.org/10.1016/j.ejca.2014.04.015
31 https://doi.org/10.1016/j.jchromb.2013.03.017
32 https://doi.org/10.1016/s1470-2045(14)70012-9
33 https://doi.org/10.1016/s1470-2045(14)70051-8
34 https://doi.org/10.1056/nejme1111636
35 https://doi.org/10.1056/nejmoa1002011
36 https://doi.org/10.1056/nejmoa1103782
37 https://doi.org/10.1056/nejmoa1112302
38 https://doi.org/10.1074/jbc.m112.377218
39 https://doi.org/10.1093/annonc/mdt587
40 https://doi.org/10.1097/ftd.0000000000000097
41 https://doi.org/10.1111/bjd.12555
42 https://doi.org/10.1111/jdv.12322
43 https://doi.org/10.1111/jdv.12685
44 https://doi.org/10.1158/1078-0432.ccr-06-2610
45 https://doi.org/10.1200/jco.2010.28.5478
46 https://doi.org/10.1200/jco.2012.43.5362
47 https://doi.org/10.1371/journal.pone.0042875
48 https://doi.org/10.3892/or.2013.2553
49 schema:datePublished 2016-02
50 schema:datePublishedReg 2016-02-01
51 schema:description Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF (V600) -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship are lacking. The aim of this prospective, multicenter study was to explore the PK/PD relationship for vemurafenib in outpatients with advanced BRAF-mutated melanoma. Fifty-nine patients treated with single-agent vemurafenib were prospectively analyzed. Vemurafenib plasma concentration (n = 159) was measured at days 15, 30, 60, and 90 after treatment initiation. Clinical and biological determinants (including plasma vemurafenib concentration) for efficacy and safety were assessed using Cox's model and multivariate stepwise logistic regression. Median progression-free survival (PFS) and overall survival were 5.0 (95 % confidence interval [95 % CI] 2.0-6.0) and 11.0 (95% CI 7.0-16.0) months, respectively. Twenty-nine patients (49 %) experienced any grade ≥3 toxicity and the most frequent grade ≥2 toxicity was skin rash (37 %). Severe toxicities led to definitive discontinuation in seven patients (12 %). Grade ≥2 skin rash was not statistically associated with better objective response at day 60 (p = 0.06) and longer PFS (hazard ratio 0.47; 95 % CI 0.21-1.08; p = 0.075). Grade ≥2 skin rash was statistically increased in patients with ECOG  ≥ 1 (odds ratio 4.67; 95 % CI 1.39-15.70; p = 0.012). Vemurafenib concentration below 40.4 mg/L at day 15 was significantly associated with a shorter PFS (1.5 [0.5-5.5] vs. 4.5 [2-undetermined] months, p = 0.029). Finally, vemurafenib concentration was significantly greater in patients developing grade ≥2 rash (61.7 ± 25.0 vs. 36.3 ± 17.9 mg/L, p < 0.0001). These results suggest that early plasma drug monitoring may help identify outpatients at high risk of non-response or grade ≥ 2 skin rash.
52 schema:genre research_article
53 schema:inLanguage en
54 schema:isAccessibleForFree false
55 schema:isPartOf Nb396aa9ece27435b986c7cf16a274252
56 Ndda162e35fb9447ba093a02384a003de
57 sg:journal.1036678
58 schema:name Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma
59 schema:pagination 59-69
60 schema:productId N3748302936b046978cd78df88aba179c
61 N415c9668a7084107bbf2a66e68d6ada5
62 N76297ed2741f429f98cb206e61ed737a
63 Nb2c63fcbc77e4f668fd4b6ef1564168a
64 Neb890dbac78f478b9c17ac286fb1b275
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024629328
66 https://doi.org/10.1007/s11523-015-0375-8
67 schema:sdDatePublished 2019-04-11T00:18
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher Nb39683f9cd904c68bd57270ca9dabe63
70 schema:url http://link.springer.com/10.1007%2Fs11523-015-0375-8
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N06ece91d16244729adf5741efc67b15b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Aged
76 rdf:type schema:DefinedTerm
77 N14031a1b8a2e46bfacb0ce00231ab8aa rdf:first sg:person.014013125204.39
78 rdf:rest N31dce7b1c319460b9008e0abe0069851
79 N14fd67d96f7f4899a163b45a905beb4c rdf:first sg:person.01301313751.52
80 rdf:rest N27b150be13e348c6b5e312456fa4b94c
81 N16a3719b409543738f6e3f7f095b5ef8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Melanoma
83 rdf:type schema:DefinedTerm
84 N174cdd725a9149938b96c55f54d062ee rdf:first sg:person.01006222554.89
85 rdf:rest N7d3650f307a44366bcde00c18e74b7dc
86 N224706ae42454e64a0bb9c0e03355894 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Sulfonamides
88 rdf:type schema:DefinedTerm
89 N2458e8c5c8f24e9b9370dafb827f1b75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Proto-Oncogene Proteins B-raf
91 rdf:type schema:DefinedTerm
92 N26022bc4fc6a4e20b6fef6a0d990044f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Humans
94 rdf:type schema:DefinedTerm
95 N27b150be13e348c6b5e312456fa4b94c rdf:first sg:person.064653677.90
96 rdf:rest N6b2cd526e52c40d581cc9df2601cd425
97 N2aaabcd892404f1ebd7fc2d1b574a1b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Prospective Studies
99 rdf:type schema:DefinedTerm
100 N2abcd0124bb54143a0980aac3363b51b rdf:first sg:person.0771215027.86
101 rdf:rest N9f206778e3b14e26b917957c93d817ce
102 N31dce7b1c319460b9008e0abe0069851 rdf:first sg:person.0731567765.18
103 rdf:rest N2abcd0124bb54143a0980aac3363b51b
104 N33625b98dffd4d72ae4fa0065d02e8cd rdf:first sg:person.0731117162.51
105 rdf:rest Nc7599b06797444638d7bad482fb853e4
106 N3748302936b046978cd78df88aba179c schema:name nlm_unique_id
107 schema:value 101270595
108 rdf:type schema:PropertyValue
109 N3c751e3cc55e4da1ad13a48910b1938a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Middle Aged
111 rdf:type schema:DefinedTerm
112 N415c9668a7084107bbf2a66e68d6ada5 schema:name readcube_id
113 schema:value 7555d0ed37f88fd4244dbbfdaeb5f613b9389ec2e66fd76aedbe095d5b486c42
114 rdf:type schema:PropertyValue
115 N4c1276b9674c433e97f5f945e943b1ae rdf:first sg:person.0714461244.43
116 rdf:rest N9339a24157184f2e819f23cf12cfaf95
117 N5ea7d35794624c97b066c4c056bde389 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Mutation
119 rdf:type schema:DefinedTerm
120 N6b2cd526e52c40d581cc9df2601cd425 rdf:first sg:person.01216754433.13
121 rdf:rest N14031a1b8a2e46bfacb0ce00231ab8aa
122 N76297ed2741f429f98cb206e61ed737a schema:name doi
123 schema:value 10.1007/s11523-015-0375-8
124 rdf:type schema:PropertyValue
125 N790c3ba7a263419dae2bb5b4afca978f rdf:first sg:person.0700337302.68
126 rdf:rest rdf:nil
127 N7d3650f307a44366bcde00c18e74b7dc rdf:first sg:person.0721531217.37
128 rdf:rest N14fd67d96f7f4899a163b45a905beb4c
129 N8a113be9f10a4ee99b0bbbe9248a9233 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Indoles
131 rdf:type schema:DefinedTerm
132 N8fb4a04137664aa393b9ae9eb9c6015d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Female
134 rdf:type schema:DefinedTerm
135 N9339a24157184f2e819f23cf12cfaf95 rdf:first sg:person.0674476202.23
136 rdf:rest N33625b98dffd4d72ae4fa0065d02e8cd
137 N9f206778e3b14e26b917957c93d817ce rdf:first sg:person.0664102115.50
138 rdf:rest N790c3ba7a263419dae2bb5b4afca978f
139 Na120ca395d524ed59ba1af879ec3c01b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Neoplasm Staging
141 rdf:type schema:DefinedTerm
142 Na42995b51eaa447fabc1a5e7114f1f2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Male
144 rdf:type schema:DefinedTerm
145 Nac77903b9f714419a4bb3181ebdebe6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Follow-Up Studies
147 rdf:type schema:DefinedTerm
148 Nb2c63fcbc77e4f668fd4b6ef1564168a schema:name pubmed_id
149 schema:value 26208946
150 rdf:type schema:PropertyValue
151 Nb39683f9cd904c68bd57270ca9dabe63 schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 Nb396aa9ece27435b986c7cf16a274252 schema:issueNumber 1
154 rdf:type schema:PublicationIssue
155 Nc2c1cb2c55ce4caca181f5daf2e78e24 schema:name Assistance Publique Hôpitaux de Paris, Département de Dermatologie, Hôpital Bichat, Paris, France
156 rdf:type schema:Organization
157 Nc7599b06797444638d7bad482fb853e4 rdf:first sg:person.01173417137.58
158 rdf:rest N174cdd725a9149938b96c55f54d062ee
159 Ndda162e35fb9447ba093a02384a003de schema:volumeNumber 11
160 rdf:type schema:PublicationVolume
161 Ne18d94025afd4f13b2c7ea85f135c1a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Brain Neoplasms
163 rdf:type schema:DefinedTerm
164 Neb890dbac78f478b9c17ac286fb1b275 schema:name dimensions_id
165 schema:value pub.1024629328
166 rdf:type schema:PropertyValue
167 Nf97a1c7836a943d18f5144ca048e9838 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Tissue Distribution
169 rdf:type schema:DefinedTerm
170 Nfd94762e7164428e80746248e43f87d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Prognosis
172 rdf:type schema:DefinedTerm
173 Nff8f115b8e2b452db3519d4bca56a8e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Protein Kinase Inhibitors
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
180 schema:name Clinical Sciences
181 rdf:type schema:DefinedTerm
182 sg:journal.1036678 schema:issn 1776-2596
183 1776-260X
184 schema:name Targeted Oncology
185 rdf:type schema:Periodical
186 sg:person.01006222554.89 schema:affiliation https://www.grid.ac/institutes/grid.411784.f
187 schema:familyName Noe
188 schema:givenName G.
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006222554.89
190 rdf:type schema:Person
191 sg:person.01173417137.58 schema:affiliation https://www.grid.ac/institutes/grid.411439.a
192 schema:familyName Golmard
193 schema:givenName JL.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173417137.58
195 rdf:type schema:Person
196 sg:person.01216754433.13 schema:affiliation https://www.grid.ac/institutes/grid.10992.33
197 schema:familyName Vidal
198 schema:givenName M.
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216754433.13
200 rdf:type schema:Person
201 sg:person.01301313751.52 schema:affiliation https://www.grid.ac/institutes/grid.411784.f
202 schema:familyName Chapuis
203 schema:givenName N.
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301313751.52
205 rdf:type schema:Person
206 sg:person.014013125204.39 schema:affiliation https://www.grid.ac/institutes/grid.462098.1
207 schema:familyName Avril
208 schema:givenName MF.
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014013125204.39
210 rdf:type schema:Person
211 sg:person.064653677.90 schema:affiliation Nc2c1cb2c55ce4caca181f5daf2e78e24
212 schema:familyName Maubec
213 schema:givenName E.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.064653677.90
215 rdf:type schema:Person
216 sg:person.0664102115.50 schema:affiliation https://www.grid.ac/institutes/grid.462098.1
217 schema:familyName Dupin
218 schema:givenName N.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664102115.50
220 rdf:type schema:Person
221 sg:person.0674476202.23 schema:affiliation https://www.grid.ac/institutes/grid.10992.33
222 schema:familyName Thomas-Schoemann
223 schema:givenName A.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0674476202.23
225 rdf:type schema:Person
226 sg:person.0700337302.68 schema:affiliation https://www.grid.ac/institutes/grid.411784.f
227 schema:familyName Blanchet
228 schema:givenName B.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700337302.68
230 rdf:type schema:Person
231 sg:person.0714461244.43 schema:affiliation https://www.grid.ac/institutes/grid.411784.f
232 schema:familyName Kramkimel
233 schema:givenName N.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714461244.43
235 rdf:type schema:Person
236 sg:person.0721531217.37 schema:affiliation https://www.grid.ac/institutes/grid.411784.f
237 schema:familyName Regnier-Rosencher
238 schema:givenName E.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721531217.37
240 rdf:type schema:Person
241 sg:person.0731117162.51 schema:affiliation https://www.grid.ac/institutes/grid.410463.4
242 schema:familyName Sakji
243 schema:givenName L.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731117162.51
245 rdf:type schema:Person
246 sg:person.0731567765.18 schema:affiliation https://www.grid.ac/institutes/grid.411784.f
247 schema:familyName Goldwasser
248 schema:givenName F.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731567765.18
250 rdf:type schema:Person
251 sg:person.0771215027.86 schema:affiliation https://www.grid.ac/institutes/grid.16780.38
252 schema:familyName Mortier
253 schema:givenName L.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771215027.86
255 rdf:type schema:Person
256 sg:pub.10.1007/s10637-011-9764-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003074905
257 https://doi.org/10.1007/s10637-011-9764-8
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/s10637-014-0178-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046029131
260 https://doi.org/10.1007/s10637-014-0178-2
261 rdf:type schema:CreativeWork
262 sg:pub.10.1007/s40262-013-0058-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014765401
263 https://doi.org/10.1007/s40262-013-0058-5
264 rdf:type schema:CreativeWork
265 sg:pub.10.1007/s40262-013-0108-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1051525212
266 https://doi.org/10.1007/s40262-013-0108-z
267 rdf:type schema:CreativeWork
268 sg:pub.10.1007/s40262-014-0137-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019983223
269 https://doi.org/10.1007/s40262-014-0137-2
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1001/jamadermatol.2013.5278 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048056832
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1002/cncr.28709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024462353
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1016/j.critrevonc.2014.07.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003607426
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1016/j.ejca.2013.01.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005388140
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1016/j.ejca.2014.04.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006806779
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1016/j.jchromb.2013.03.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047456287
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1016/s1470-2045(14)70012-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038277880
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1016/s1470-2045(14)70051-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027593875
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1056/nejme1111636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004286834
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1056/nejmoa1002011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012824919
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1056/nejmoa1103782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041864150
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1056/nejmoa1112302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051449373
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1074/jbc.m112.377218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009999164
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1093/annonc/mdt587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004160739
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1097/ftd.0000000000000097 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035271330
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1111/bjd.12555 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014339721
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1111/jdv.12322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048575620
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1111/jdv.12685 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024465753
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1158/1078-0432.ccr-06-2610 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022246580
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1200/jco.2010.28.5478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042676361
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1200/jco.2012.43.5362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041701145
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1371/journal.pone.0042875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015676476
314 rdf:type schema:CreativeWork
315 https://doi.org/10.3892/or.2013.2553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071532515
316 rdf:type schema:CreativeWork
317 https://www.grid.ac/institutes/grid.10992.33 schema:alternateName Paris Descartes University
318 schema:name Assistance Publique Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
319 Centre d’étude et de recours sur les inhibiteurs de l’angiogénèse (CERIA), Paris, France
320 UMR8638 CNRS, UFR de Pharmacie, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
321 rdf:type schema:Organization
322 https://www.grid.ac/institutes/grid.16780.38 schema:alternateName Université Lille 2 Droit et Santé
323 schema:name CHRU de Lille, Service de Dermatologie, Paris, France
324 INSERM U 837, Faculté de Médecine, Université de Lille II, Lille, France
325 rdf:type schema:Organization
326 https://www.grid.ac/institutes/grid.410463.4 schema:alternateName Centre Hospitalier Regional et Universitaire de Lille
327 schema:name CHRU de Lille, Service de Dermatologie, Paris, France
328 rdf:type schema:Organization
329 https://www.grid.ac/institutes/grid.411439.a schema:alternateName Pitié-Salpêtrière Hospital
330 schema:name Assistance Publique Hôpitaux de Paris, Département de Biostatistiques, Hôpital Pitié-Salpêtrière, Paris, France
331 rdf:type schema:Organization
332 https://www.grid.ac/institutes/grid.411784.f schema:alternateName Hôpital Cochin
333 schema:name Assistance Publique Hôpitaux de Paris, Département de Dermatologie, Hôpital Cochin, Paris, France
334 Assistance Publique Hôpitaux de Paris, Service de Cancérologie médicale, Hôpital Cochin, Paris, France
335 Assistance Publique Hôpitaux de Paris, Service d’Hématologie biologique, Hôpital Cochin, Paris, France
336 Assistance Publique Hôpitaux de Paris, Unité Fonctionnelle de Pharmacocinétique et Pharmacochimie, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014, Paris, France
337 Centre d’étude et de recours sur les inhibiteurs de l’angiogénèse (CERIA), Paris, France
338 Institut Cochin, Institut National de la Sante et de la Recherche Médicale (INSERM) U1016, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Faculté de médecine, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
339 rdf:type schema:Organization
340 https://www.grid.ac/institutes/grid.462098.1 schema:alternateName Institut Cochin
341 schema:name Assistance Publique Hôpitaux de Paris, Département de Dermatologie, Hôpital Cochin, Paris, France
342 Institut Cochin, Institut National de la Sante et de la Recherche Médicale (INSERM) U1016, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8104, Faculté de médecine, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France
343 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...